- Home
- ACIU vs CIO Comparison
ACIU vs CIO Comparison
Compare ACIU & CIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- CIO
- Stock Information
- Founded
- ACIU 2003
- CIO 2013
- Country
- ACIU Switzerland
- CIO Canada
- Employees
- ACIU N/A
- CIO N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- CIO Real Estate Investment Trusts
- Sector
- ACIU Health Care
- CIO Real Estate
- Exchange
- ACIU Nasdaq
- CIO Nasdaq
- Market Cap
- ACIU 173.7M
- CIO 202.0M
- IPO Year
- ACIU 2016
- CIO 2014
- Fundamental
- Price
- ACIU $1.69
- CIO $4.85
- Analyst Decision
- ACIU Strong Buy
- CIO
- Analyst Count
- ACIU 2
- CIO 0
- Target Price
- ACIU $10.00
- CIO N/A
- AVG Volume (30 Days)
- ACIU 137.1K
- CIO 196.2K
- Earning Date
- ACIU 04-30-2025
- CIO 05-02-2025
- Dividend Yield
- ACIU N/A
- CIO 8.21%
- EPS Growth
- ACIU N/A
- CIO N/A
- EPS
- ACIU N/A
- CIO N/A
- Revenue
- ACIU $32,014,254.00
- CIO $168,891,000.00
- Revenue This Year
- ACIU N/A
- CIO $1.25
- Revenue Next Year
- ACIU $676.94
- CIO $3.42
- P/E Ratio
- ACIU N/A
- CIO N/A
- Revenue Growth
- ACIU 91.20
- CIO N/A
- 52 Week Low
- ACIU $1.43
- CIO $4.19
- 52 Week High
- ACIU $4.98
- CIO $6.50
- Technical
- Relative Strength Index (RSI)
- ACIU 46.75
- CIO 46.23
- Support Level
- ACIU $1.55
- CIO $4.78
- Resistance Level
- ACIU $1.79
- CIO $4.95
- Average True Range (ATR)
- ACIU 0.10
- CIO 0.17
- MACD
- ACIU 0.03
- CIO -0.01
- Stochastic Oscillator
- ACIU 66.67
- CIO 12.12
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.